EGTX highlights tiratricol progress ahead of near-term PDUFA
The company is advancing tiratricol for MCT8 deficiency and points to robust clinical data, expanding presence, and an upcoming PDUFA date.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.